Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Pernot

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
JNCI Cancer Spectrum|September 29, 2023
Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter studyAziz Zaanan, Julie Henriques, Anthony Turpin, et al.
British Journal of Cancer|September 16, 2015
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohortAlix Portal, Simon Pernot, David Tougeron, et al.
International Journal of Cancer|December 23, 2022
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO studyMarie Auvray Kuentz, Vincent Hautefeuille, Louis de Mestier, et al.
Journal for Immunotherapy of Cancer|January 4, 2025
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitorsJulien Taieb, Margherita Ambrosini, Emily Alouani, et al.
Future Oncology (London, England)|November 12, 2024
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancerJean-David Fumet, Nicolas Roussot, Aurélie Bertaut, et al.
Eclinicalmedicine|June 8, 2026
Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France)Julien Taieb, Simon Pernot, Frédéric Thuillier, et al.
Molecular Cancer|September 13, 2024
Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomicsSophie Cousin, Jean-Philippe Guégan, Kohei Shitara, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|July 4, 2019
Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significanceSimon Pernot, Magali Terme, Nina Radosevic-Robin, et al.
Gut|January 2, 2023
AGR2 protein expression in colorectal tumour epithelialcompartmentEric Chevet, F Bassal, Stéphanie Beq, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitorsClaire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
JNCI Cancer Spectrum|September 29, 2023
Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter studyAziz Zaanan, Julie Henriques, Anthony Turpin, et al.
British Journal of Cancer|September 16, 2015
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohortAlix Portal, Simon Pernot, David Tougeron, et al.
International Journal of Cancer|December 23, 2022
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO studyMarie Auvray Kuentz, Vincent Hautefeuille, Louis de Mestier, et al.
Journal for Immunotherapy of Cancer|January 4, 2025
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitorsJulien Taieb, Margherita Ambrosini, Emily Alouani, et al.
Future Oncology (London, England)|November 12, 2024
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancerJean-David Fumet, Nicolas Roussot, Aurélie Bertaut, et al.
Eclinicalmedicine|June 8, 2026
Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France)Julien Taieb, Simon Pernot, Frédéric Thuillier, et al.
Molecular Cancer|September 13, 2024
Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomicsSophie Cousin, Jean-Philippe Guégan, Kohei Shitara, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|July 4, 2019
Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significanceSimon Pernot, Magali Terme, Nina Radosevic-Robin, et al.
Gut|January 2, 2023
AGR2 protein expression in colorectal tumour epithelialcompartmentEric Chevet, F Bassal, Stéphanie Beq, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitorsClaire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
Pageof 11